Ariosa Diagnostics Wins Summary Judgment Against Sequenom on Cell-free DNA Patent

  Ariosa Diagnostics Wins Summary Judgment Against Sequenom on Cell-free DNA

PR Newswire

SAN JOSE, Calif., Oct. 31, 2013

SAN JOSE, Calif., Oct. 31, 2013 /PRNewswire/ --Ariosa Diagnostics, Inc., won
summary judgment yesterday in a patent infringement litigation involving U.S.
Patent No. 6,258,540 against Sequenom, Inc., an exclusive licensee of the
patent from Isis Innovations, Inc. The United States District Court for the
Northern District of California invalidated the '540 patent at issue, giving
Ariosa a complete victory in the case. The patent at issue is related to the
detection of fetal cell-free DNA in the bloodstream of pregnant women, and
Sequenom claimed that it applied to tests for the determination of certain
fetal genetic characteristics. The Court invalidated Sequenom's patent because
it attempts to cover this natural phenomenon, which the Court found is not
patent-eligible subject matter.


"Ariosa is an innovator in prenatal testing, and we are extremely pleased with
the Court's decision in our favor," said Dianna DeVore, vice president of
intellectual property and legal affairs at Ariosa Diagnostics. The ruling
extends established Supreme Court and Federal Circuit precedent, and validates
Ariosa's long-standing view that it has freedom to develop new, innovative and
market-leading technologies to provide improved genetic testing for pregnant

In light of repeated public threats by Sequenom regarding enforcement of its
'540 patent, Ariosa filed suit against Sequenom in December 2011, seeking a
declaratory judgment that its Harmony™ Prenatal Test did not infringe
Sequenom's patent. Sequenom counterclaimed for patent infringement and moved
for a preliminary injunction.

Sequenom unsuccessfully spent almost two years trying to prevent Ariosa from
making and sellingthe Harmony Prenatal Test, a proprietary and innovative
test that provides important information about whether a fetus is at risk of
having certain chromosomal abnormalities, including Down syndrome, based on a
simple blood draw from a pregnant woman.

Ariosa is represented in the litigation by Irell & Manella LLP.

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to
innovating together to improve patient care. The flagship product, the
Harmony™ Prenatal Test, is a safe, highly accurate and affordable prenatal
test for maternal and fetal health. Led by an experienced team, Ariosa is
using its proprietary technology to perform a directed analysis of cell-free
DNA in blood. The Harmony™ Prenatal Test equips pregnant women and their
healthcare providers with reliable information to make decisions regarding
their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif.
For more information, Follow us on Twitter
@HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

Jen Bruursema

SOURCE Ariosa Diagnostics, Inc.

Press spacebar to pause and continue. Press esc to stop.